Design Therapeutics, Inc. Profile Avatar - Palmy Investing

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia…

Biotechnology
US, Carlsbad [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of DSGN's Analysis
CIK: 1807120 CUSIP: 25056L103 ISIN: US25056L1035 LEI: - UEI: -
Secondary Listings
DSGN has no secondary listings inside our databases.